SCHEMBL21393490

SCHEMBL21393490

COCc1cc(OC)ccc1OCc1cncc(C(=O)OC)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.48
CYP11B2 P19099 2/20 0.48
MTNR1A P48039 6/20 0.46
MTNR1B P49286 5/20 0.46
SGMS2 Q8NHU3 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.42
LRRK2 Q5S007 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGER1 P34995 2/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15065486 0.83 KDM4E (0.48) CYP11B1CYP11B2MRGPRX4LRRK2CYP1A2
SCHEMBL31371510 0.80 KMT2A (0.54) MTNR1AMTNR1BCYP1A2CYP3A4MAPT
SCHEMBL20094653 0.78 ATM (0.59) CYP11B1CYP11B2CYP2C9CYP2C19ATM
SCHEMBL12751782 0.75 L3MBTL1 (0.54) MRGPRX4MAPTPTGER1ATM
SCHEMBL15065166 0.73 MRGPRX4 (0.50) CYP11B1CYP11B2MRGPRX4LRRK2SMN1; SMN2
SCHEMBL23434961 0.72 MAPT (0.54) MTNR1AMTNR1BCYP1A2CYP3A4MAPT
SCHEMBL2014936 0.72 GYS1 (0.56) CYP11B1CYP11B2
SCHEMBL21393493 0.71 MTNR1A (0.47) MTNR1AMTNR1BCYP1A2CYP3A4MAPT
SCHEMBL693288 0.71 RAB9A (0.60) CYP3A4MAPTSMN1; SMN2
SCHEMBL31371257 0.71 RAB9A (0.63) MTNR1AMTNR1BMRGPRX4MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019182938-A1 AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE VIRGINIA COMMONWEALTH UNIVERSITY (US) 2019-09-26 WO disclosed